The “Rutan, 100 mg” drug, developed by scientists of the Institute of Bioorganic Chemistry of the Academy of Sciences of the Republic of Uzbekistan, is included in the protocol for the treatment of patients with COVID-19. This was announced by the Head of the Press Service of the Ministry of Innovative Development of the Republic of Uzbekistan Nazokat Abdukunduzova.

The Ministry of Health approved the use of the drug on the recommendation of a doctor in the treatment of patients with coronavirus, as well as at the first signs of weakness associated with an acute respiratory infection. It is derived from the plant Rhus coriaria and showed effectiveness against various strains of the influenza virus and SARS-Cov-2 virus during clinical trials.

Clinical trials have also shown that the drug can be used from the age of seven, and taking pills 2 times a day helps prevent the reproduction of the virus, further inflammations, acute and atypical pneumonia. It is also able to stop the two main conservative enzymes involved in the formation of all functional and structural proteins of the virus that have a pathological effect – 3CL protease and RNA-dependent RNA polymerase. Structural and functional proteins do not appear in the body and immature viruses are formed that cannot infect. The drug has pronounced antihypoxic, membrane-stabilizing, anti-radical, antioxidant properties. The level of toxicity is very low, there are practically no side effects.